Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scientists identify protein critical to melanoma growth

21.12.2004


Researchers at Dana-Farber Cancer Institute and Children’s Hospital Boston have discovered that malignant melanoma, the potentially lethal skin cancer, can’t grow without a steady supply of a protein that normal cells can do without.



The findings, which are published in the December issue of Cancer Cell, suggest that drugs that cut off melanoma cells’ supply of the protein, called CDK2, might curb the growth of the dangerous skin cancer in patients, and with relatively low toxicity. In theory, such a drug would leave normal cells unharmed and have many fewer side effects compared to standard chemotherapy.

Working with melanoma cells grown in the laboratory, the researchers, led by David E. Fisher, MD, PhD, Director of the Melanoma Program at Dana-Farber and the paper’s senior author, showed that adding a chemical that quashed the activity of CDK2, the gene that manufactures CDK2 protein, dramatically slowed the growth and proliferation of the cancer cells. Unlike conventional chemotherapy drugs, a CDK2 inhibitor drug wouldn’t be aimed at killing melanoma cells, only halting their growth.


Fisher said that CDK2-inhibiting drugs exist, and he hopes that the research results will soon lead to clinical trials of them in patients with melanoma.

The study’s lead author is Jinyan Du, PhD, who carried out the project while working as a student in Fisher’s lab at Dana-Farber. Fisher is also a pediatric oncologist at Dana-Farber/Children’s Hospital Cancer Care.

The CDK2 gene and its protein (an enzyme) are one of several regulators of the cell cycle: That is, they help determine when a cell should be "resting" and when it should begin dividing to make more of itself. When cells become malignant, it is in part because their normal controls on growth and division are disabled, and they proliferate abnormally. Overactive CDK2 has been found in many types of cancer, making it a prime candidate for designer drugs that would turn down CDK2 activity and, it was hoped, slow the runaway growth of cancer cells.

Recent research, however, had thrown cold water on the notion. Studies have shown that tumor cells in a variety of cancers weren’t dependent on CDK2 for growth. Thus, blocking its activity had little effect on the out-of-control cells.

The scientist’s report today is all the more striking, because it reveals that melanoma does require the CDK2 enzyme for growth. Why this is so isn’t clear, but the finding revives the strategy of using CDK2 inhibitors as a potential treatment – even if only for this one form of cancer. And, since it’s been previously shown that normal cells can divide and grow normally without CDK2 (other types of CDK molecules apparently can take over the job) "this is good news, because it means there may be little toxicity to a person who would receive a CDK2 inhibitor to treat melanoma," says Fisher, who is also an associate professor of pediatrics at Harvard Medical School.

Melanoma will cause about 7,900 deaths this year in the United States, according to the American Cancer Society. Its incidence has been rising rapidly over the past several decades: about 55,000 cases are expected in 2004. Most cases caught early can be cured, but if melanoma cells penetrate the skin deeply, the cancer is highly prone to spread with life-threatening consequences despite treatment with surgery, chemotherapy and radiation.

The new findings stem from Fisher’s longtime work on a gene called MITF that regulates the development of skin pigment-producing cells called melanocytes. Regulatory genes like MITF act on other genes in a chain-of-command fashion. When Fisher’s group looked for genes regulated by MITF, they found a pigment gene called SILVER, and they noted that, surprisingly, it was located just a stone’s throw, genetically, from CDK2 on the chromosome.

"It was dumb luck," says Fisher, and it led him and his colleagues to recognize that both SILVER and CDK2 were under the control of MITF. In all other body cells besides melanocytes, CDK2 is not subservient to MITF: To the researchers this was an important clue. "If the control of CDK2 expression is so different in the development of melanocytes, then maybe the requirement for CDK2 in melanoma is different than in other cancers," he says – and the new findings confirm this idea.

The fact that melanoma cells, unlike other cancer cells, become "overdependent" on the CDK2 protein while normal cells don’t need much of it provides a "therapeutic window." That is, a drug that suppresses melanoma growth by shutting down CDK2 in theory could control the cancer yet have little toxic effect on the body.

In addition to Fisher and Du, the paper’s other authors include researchers from the Broad Institute at the Massachusetts Institute of Technology and Harvard University, MIT, and Massachusetts General Hospital. The research was funded by the National Institutes of Health.

Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.

Janet Haley Dubow | EurekAlert!
Further information:
http://www.dfci.harvard.edu
http://www.childrenshospital.org

More articles from Life Sciences:

nachricht Fine organic particles in the atmosphere are more often solid glass beads than liquid oil droplets
21.04.2017 | Max-Planck-Institut für Chemie

nachricht Study overturns seminal research about the developing nervous system
21.04.2017 | University of California - Los Angeles Health Sciences

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

Im Focus: Quantum-physical Model System

Computer-assisted methods aid Heidelberg physicists in reproducing experiment with ultracold atoms

Two researchers at Heidelberg University have developed a model system that enables a better understanding of the processes in a quantum-physical experiment...

Im Focus: Glacier bacteria’s contribution to carbon cycling

Glaciers might seem rather inhospitable environments. However, they are home to a diverse and vibrant microbial community. It’s becoming increasingly clear that they play a bigger role in the carbon cycle than previously thought.

A new study, now published in the journal Nature Geoscience, shows how microbial communities in melting glaciers contribute to the Earth’s carbon cycle, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

New quantum liquid crystals may play role in future of computers

21.04.2017 | Physics and Astronomy

A promising target for kidney fibrosis

21.04.2017 | Health and Medicine

Light rays from a supernova bent by the curvature of space-time around a galaxy

21.04.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>